Chapel Hill startup with ties to UNC lands rights to drug offering hope to cystic fibrosis patients

Posted Oct 27, 2019
Path BioAnalytics (PBA), a precision medicine startup with ties to UNC, has scored the rights to a new drug therapy offering hope to cystic fibrosis (CF) patients with rare mutations. PBA is a graduate of Launch Chapel Hill, an accelerator program based in Chapel Hill, as well as the Kenan Flagler Business School program Startup UNC. (WRAL Tech Wire)

Related: Campus Connections

Carolina puts on a show for the Class of 2026
For Carolina’s graduates, the party’s been going on for weeks now. The good times continued during Spring Commencement Saturday night at Kenan Stadium. Country music...
Sun May 10, 2026

Look back at UNC Commencement through the years
UNC celebrates the newest Tar Heel graduates at Spring Commencement on Saturday at Kenan Stadium. Commencement has a long history at Carolina. UNC was the...
Sat May 9, 2026

UNC Commencement Weekend Athletic Events Know Before You Go
With several home athletic events and commencement ceremonies dotting campus, parking will be complicated in Chapel Hill this weekend. Women's Tennis, Women's Lacrosse and Men's...
Fri May 8, 2026

Heart of a Heel encourages organ donor registration
Three Carolina seniors used experiences from their undergraduate studies and inspirational stories from other Tar Heels to help save lives. Rotimi Kukoyi, Emma Montero and...
Tue May 5, 2026